1

2

3

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1

Fanglei Zuo¹, Ph.D., Rui Sun¹, M.S., Hassan Abolhassani¹, Ph.D., Likun Du¹, Ph.D., Yating Wang¹, M.S., Stelios
Vlachiotis¹, M.S., Federico Bertoglio², Ph.D., Maren Schubert², Ph.D., Nima Rezaei³, Ph.D., Zahra
Chavoshzadeh⁴, M.D., Concetta Guerra⁵, Ph.D., Andrea Cavalli⁵, Ph.D., Juni Andréll⁶, Ph.D., Makiko
Kumagai-Braesch⁷, Ph.D., Yintong Xue⁸, Ph.D., Yunlong Cao^{9,10}, Ph.D., Michael Hust², Ph.D., Davide F.
Robbiani⁵, Ph.D., Xiaoliang Sunney Xie^{9,10}, Ph.D., Lennart Hammarström^{1#}, Ph.D., Harold Marcotte^{1#}, Ph.D.,
Qiang Pan-Hammarström^{1#}, Ph.D.

10

- 11 ¹Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
- ²Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics;
 Departments of Biotechnology and Medical Biotechnology, Braunschweig, Germany.
- ³*Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran*
- 15 University of Medical Sciences, Tehran, Iran.
- ⁴Pediatric Infections Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical
 Sciences, Tehran, Iran.
- ⁵*Institute for Research in Biomedicine, Università della Svizzera italiana; Bellinzona, Switzerland.*
- ⁶Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University, Stockholm,
 Sweden.
- ⁷Division of Transplantation Surgery, CLINTEC, Karolinska Institutet at Karolinska University Hospital,
 Stockholm, Sweden.
- 23 ⁸Department of Immunology, Peking University Health Science Center, Beijing, P.R. China.
- ⁹Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China.
- 25 ¹⁰Changping Laboratory, Beijing, P.R. China.
- 26
- 27
- 28 # These authors jointly supervised this work
- 29 Leading contact: qiang.pan-hammarstrom@ki.se
- 30
- 31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 Abstract

The emergence of highly immune-escape Omicron variants of the severe acute respiratory syndrome coronavirus 33 2 (SARS-CoV-2), such as BQ and XBB, has led to concerns about the efficacy of vaccines. Using 34 lentivirus-based pseudovirus neutralizing assay, we showed that heterologous vaccination involving parental 35 mRNA vaccine as a booster or second booster in individuals that received two or three doses of inactivated 36 vaccines strongly augments the neutralizing activity against emerging Omicron subvariants, including BF.7, 37 BQ.1.1, and XBB.1, by 4.3- to 219-folds. Therefore, a heterologous boosting strategy with mRNA-based 38 vaccines should be considered in populations where inactivated vaccines were primarily used. 39

- 40
- 41

Text 42

The emergence of highly immune-escape Omicron variants of the severe acute respiratory syndrome coronavirus 43 2 (SARS-CoV-2) has led to concerns about the efficacy of vaccines and therapeutic monoclonal antibodies. 44 45 Omicron subvariants BA.4.6, BF.7, BQ.1.1, XBB, and XBB.1 harbor the spike protein R346T substitution which 46 contributes to evasion of class III anti-spike monoclonal antibody recognition while XBB, and XBB.1.1 47 subvariants harbor the F486S substitution which reduces binding for class I and II monoclonal antibodies.¹ BQ.1, BQ.1.1, XBB, and XBB.1 are increasing rapidly in the United States, India, Europe, and other parts of the world. 48 whereas BF.7 is one of the dominant strains currently circulating in China. Due to humoral immune imprinting, a 49 phenomenon in which initial exposure to the original strain of SARS-CoV-2, by infection or vaccination, limits a 50 person's future immune response against variants, the bivalent vaccine booster and hybrid immunity may not 51 provide sufficient protection against emerging Omicron subvariants.²⁻⁴ We have previously shown that an mRNA 52 vaccine booster in individuals vaccinated with two doses of inactivated vaccine significantly increased the level 53 of plasma neutralizing antibodies against Omicron BA.1.⁵ Whether this vaccination strategy retains neutralizing 54 55 activity against the emerging Omicron subvariants remains unknown.

56

We used enzyme-linked immunosorbent assay and lentivirus-based pseudovirus neutralizing assay (see the 57 Supplementary Methods section in the Supplementary Appendix), to evaluate the levels of binding and 58 59 neutralizing antibodies in 77 plasma samples collected from 67 healthy volunteers within 1-5 months after 60 vaccination or infection (Table S1). The participants were grouped based on their vaccination and infection 61 history: three doses of inactivated vaccine; three doses of mRNA vaccine; two doses of inactivated vaccine 62 followed by an mRNA vaccine booster; three doses of inactivated vaccine followed by one or two doses of 63 mRNA vaccine booster; infected during the G614 wave and sampled after one or two subsequent doses of 64 mRNA vaccine; and breakthrough infection during the Omicron BA.1 wave.

65

In all six groups, the level of receptor-binding domain (RBD)-specific IgG and the neutralizing activity were 66 lower against all Omicron subvariants tested than the original G614 strain, with the lowest level measured 67 against the XBB.1 subvariant (Fig. S1, Fig. 1, and Fig. S2). The level of specific IgG and half-maximal 68 pseudovirus neutralization titers (NT50) against Omicron subvariants in the heterologous vaccination groups 69 70 were significantly higher than that in individuals receiving three doses of a homologous inactivated vaccine,

reaching a level similar to those who received three doses of homologous mRNA-vaccine or a boost of mRNA 71 72 vaccine after infection or experienced breakthrough infection (Fig. S1 and Fig. 1). The NT50 of heterologous vaccination groups were 155- to 158-folds higher against G614 and 4.3- to 219-folds higher against Omicron 73 74 subvariants than that of three doses of a homologous inactivated vaccine group (Fig. 1). Although the median 75 NT50 values of each vaccinated/infected group against BF.7, BO.1.1, and XBB.1 were 4- to 148-fold lower compared to that against G614, the median NT50 values against these Omicron subvariants were 17 to 512 in the 76 77 heterologous vaccination groups as well as homologous mRNA vaccine group, while those in three doses of a homologous inactivated vaccine group were below the limit of detection (Fig. S2B) and may account for the 78 surge of COVID-19 cases in China where inactivated vaccines are mainly used. 79

80

Thus, among all omicron subvariants tested, the lowest neutralization activity elicited by vaccines and BTI was 81 against BQ.1.1, and XBB.1. Our results suggest that heterologous vaccination involving parental mRNA vaccine 82 83 as a booster or second booster in individuals that received two/three doses of inactivated vaccines strongly 84 augments the neutralizing activity and may still be effective against emerging Omicron subvariants. Therefore, a 85 heterologous boosting strategy with mRNA-based vaccines should be considered in populations where 86 inactivated vaccines were primarily used.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.02.23285205; this version posted February 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

87 Acknowledgments

This work was supported by The European Union's Horizon 2020 research and innovation program (ATAC, 88

101003650, D.F.R., M.H., L.H., H.M., O.P.H), the Center for Innovative Medicine at the Karolinska Institutet 89

- 90 (FoUI-963219, Q.P.H), the Swedish Research Council (2019-01302, 2020-06116, Q.P.H), the Knut and Alice
- Wallenberg Foundation (KAW2020.0102, L.H., O.P.H), and the Magnus Bergvalls Stiftelse (2022-111, F.Z). 91
- 92

Competing interests 93

- The authors declare no competing interests. 94
- 95

References 96


- Ou, P., Evans, J.P., Faraone, J.N., et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron 97 1. subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe 2023;31:9-17. 98 doi.org/10.1016/i.chom.2022.11.012 99
- 100 2. Kurhade, C., Zou, J., Xia, H., et al. Low neutralization of SARS-CoV-2 Omicron BA. 2.75. 2, BQ. 1.1, 101 and XBB. 1 by parental mRNA vaccine or a BA. 5-bivalent booster. Nat Med 2022;
- doi.org/10.1038/s41591-022-02162-x. 102
- 3. Cao, Y., Jian, F., Wang, J., et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron 103 RBD evolution. Nature 2022; doi.org/10.1038/s41586-022-05644-7. 104
- Wang, Q., Bowen, A., Valdez, R., et al. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. N 105 4. Engl J Med 2023; doi: 10.1056/NEJMc2213907. 106
- 107 Zuo, F., Abolhassani, H., Du, L., et al. Heterologous immunization with inactivated vaccine followed by 5. mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun 2022;13, 108 109 2670. doi.org/10.1038/s41467-022-30340-5
- 110
- 111

medRxiv preprint doi: https://doi.org/10.1101/2023.02.02.23285205; this version posted February 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

112 Figure 1. Plasma neutralization activity against G614 and Omicron subvariants.

113 Plasma neutralization activity against the G614 strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (panel A) and the Omicron subvariants BA.2 (panel B), BA.4/5 (panel C), BF.7 (panel D), 114 BQ.1.1 (panel E), and XBB.1 (panel F) in participants who received three doses (3X) of inactivated vaccine (n =115 13), three doses of mRNA vaccine (n = 14), two doses (2X) of inactivated vaccine followed by an mRNA 116 vaccine booster (n = 16), three doses of inactivated vaccine followed by one or two doses of mRNA vaccine 117 booster (n = 5; 8 samples), one or two doses of mRNA vaccine after infection (G614 wave) (Infected plus mRNA 118 vaccine, n = 9; 11 samples) or had experienced breakthrough infection during the Omicron BA.1 wave 119 (Breakthrough infection, n = 15). The median half-maximal neutralization titers (NT50) and the ratio of the 120 121 NT50 titer of each group versus the group who received three doses of inactivated vaccine are shown on the top 122 of each panel. Symbols represent individual samples and horizontal black lines indicate the median. Whiskers indicate the interquartile range. A two-sided Mann-Whitney U test was used to compare the neutralizing activity 123 124 between three doses of inactivated vaccine group and other groups in each panel. The dashed line indicates the 125 limit of detection.



Supplementary Appendix

Table of contents

133	Methods	7
134	Study design	7
135	Production of SARS-CoV-2 RBD protein	7
136	Detection of antibodies specific to SARS-CoV-2	7
137	Neutralization assay against pseudotyped SARS-CoV-2	8
138	Quantification and statistical analysis	8
139	Data availability	8
140	References	9
141	Table S1. Demographic data of vaccinated individuals	10
142 143	Figure S1. Level of specific IgG antibodies against the receptor binding domain (RBD) of the G614 strain and Omicron subvariants	
144 145	Figure S2. Level of receptor binding domain (RBD)-specific IgG antibodies (A) and neutralization activity (B) against G614 strain and Omicron subvariants	.12
146		

medRxiv preprint doi: https://doi.org/10.1101/2023.02.02.23285205; this version posted February 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

Perpetuity. All rights reserved. No reuse allowed without permission.

148 Methods

149

150 Study design

151 Study inclusion criteria included subjects being above 18 years of age who have received inactivated and/or 152 mRNA vaccines with a documented vaccination history (type of vaccine, number of doses, the interval between the doses, days after the latest dose, if they have been infected), and who were willing and able to provide written 153 154 informed consent. The study included 77 samples from 67 healthy volunteers (64% females, median age of 31 155 years) during 2021-2022 who received three doses of inactivated vaccine CoronaVac (Sinovac) or BBIBP-CorV (Sinopharm), or three doses of an mRNA vaccine BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), or 156 157 a combination of both (two doses of inactivated vaccine followed by one or two doses of heterologous mRNA boost; or three doses of inactivated vaccine followed by one or two doses of heterologous mRNA boost), some of 158 whom had experienced breakthrough infections during the Omicron BA.1 wave. Samples were collected 9-144 159 160 days (median day 48) after dose three of inactivated vaccine, 11-121 days (median day 28.5) after each mRNA 161 vaccine dose including after mRNA heterologous boost, and 11-43 days (median day 23) after a breakthrough 162 infection (Supplementary Appendix Table 1). Infection was confirmed when an individual tested positive for 163 antigen or qPCR test. Plasma samples from pre-vaccinated, non-infected healthy donors from our cohort (n = 12, 164 Supplementary Appendix Table 1) were also collected as negative controls and used to calculate the cutoff value 165 of the ELISA method. The study was approved by the ethics committees in institutional review board (IRB) of Stockholm, and the Tehran University of Medical Sciences. 166

167

168 Production of SARS-CoV-2 RBD protein

The RBDs of G614 and Omicron (BA.1, BA.2, BA.4/5) variants were ordered as GeneString from GeneArt (Thermo Fisher Scientific). All sequences of the RBD (aa 319-541 in GenBank: MN908947) were inserted into an *NcoI/Not*I compatible variant of an OpiE2 expression vector carrying the N-terminal signal peptide of the mouse Ig heavy chain and a C-terminal 6×His-tag. RBD of G614 and Omicron were expressed in a baculovirus-free expression system in High Five insect cells and purified on HisTrap Excel columns (Cytiva) followed by size-exclusion chromatography on 16/600 Superdex 200-pg columns (Cytiva).^{1,2} The RBDs of Omicron BO.1.1 and XBB/XBB.1 were ordered from Sino Biologicals.

176

177 Detection of antibodies specific to SARS-CoV-2

For assessing the anti-RBD IgG binding activity, high-binding Corning Half area plates (Corning #3690) were 178 coated overnight at 4°C with RBD derived from the G614 and Omicron BA.1, BA.2, BA.4/5, BO.1.1, and 179 XBB/XBB.1 (1.7 µg/ml) variants in PBS. Serial dilutions of plasma in 0.1% BSA in PBS were added and plates 180 181 were subsequently incubated for 1.5 h at room temperature. Plates were then washed and incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated goat anti-human IgG (Invitrogen #A18805) 182 (diluted 1:15 000 in 0.1% BSA-PBS). Bound antibodies were detected using tetramethylbenzidine substrate 183 (Sigma #T0440). The color reaction was stopped with 0.5M H₂SO₄ after 10 min incubation and the absorbance 184 was measured at 450 nm using an ELISA plate reader. For each sample, the EC₅₀ values were calculated using 185 186 GraphPad Prism 7.04 software and expressed as relative potency towards an internal calibrant for which the

Binding Antibody Unit (BAU) was calculated using the WHO International Standard 20/136 in relation to the 187 188 G614 RBD. The positive cutoff was calculated as 2 standard deviations (2SD) above the mean of a pool of pre-vaccination samples (n = 12). 189

190

Neutralization assav against pseudotyped SARS-CoV-2 191

The human-codon optimized gene coding for the S protein of G614, BA.2, and BA.4/5 lacking the C-terminal 19 192 193 codons (S Δ 19) was synthesized by GenScript. The S Δ 19 gene of BF.1, BQ.1.1, and XBB.1 were constructed by 194 site-directed mutagenesis (QuikChange Multi Site-Directed Mutagenesis Kit, Agilent) using BA.2 or BA.4/5 $S\Delta 19$ gene as a template. To generate (HIV-1/NanoLuc2AEGFP)-SARS-CoV-2 particles, three plasmids were 195 196 used, with a reporter vector (pCCNanoLuc2AEGFP), HIV-1 structural/regulatory proteins (pHIVNLGagPol) and SARS-CoV-2 S Δ 19 carried by separate plasmids as previously described.³ 293FT cells were transfected with 7 197 μg of pHIVNLGagPol, 7 μg of pCCNanoLuc2AEGFP, and 2.5 μg of a pSARS-CoV-2-SΔ19 carrying the SΔ19 198 gene from G614 or Omicron variants (at a molar plasmid ratio of 1:1:0.45) using 66 µl of 1 mg/ml 199 200 polyethylenimine (PEI).

201

202 Five-fold serially diluted plasma samples were incubated with pseudotyped SARS-CoV-2 virus (G614, BA.2, 203 BA.4/5, BF.7, BQ.1.1, and XBB.1) for 1 h at 37 °C. The mixture was subsequently incubated with 204 ACE2-expressing HEK293T cells for analyses of G614 or Omicron pseudoviruses for 48 h, after which the cells were washed with PBS and lysed with Luciferase Cell Culture Lysis reagent (Promega). NanoLuc luciferase 205 206 activity in the lysates was measured using the Nano-Glo Luciferase Assay System (Promega) with a Tecan 207 Infinite microplate reader. The relative luminescence units were normalized to those derived from cells infected with the pseudotyped virus in the absence of plasma samples. The NT50 values for plasma were determined 208 209 using four-parameter nonlinear regression (the least squares regression method without weighting) (GraphPad 210 Prism 7.04 software).

211

212 **Ouantification and statistical analysis**

Microsoft Excel 2017 was used for data collection for this study. Two-sided Mann-Whitney U test was 213 214 performed for comparisons of anti-SARS-CoV-2 binding and neutralizing antibody levels between groups. A Wilcoxon matched-pairs signed rank test was used for the comparison of paired samples. All analyses and data 215 plotting were performed with GraphPad 7.05. A Chi-square test for trend was used to compare the gender 216 217 between groups. A Kruskal-Wallis analysis of variance (ANOVA) was performed to compare the age and 218 sampling day after vaccination/infection between groups. A p-value less than 0.05 was considered to be 219 statistically significant.

220

221 Data availability

The data that support the findings of this study are available within the Article. All other data are available from 222 223 the corresponding author upon reasonable request.

- 225 References
- 226 Bertoglio, F., Fühner, V., Ruschig, M., et al. A SARS-CoV-2 neutralizing antibody selected from 1. COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell 227 Rep 2021;**36**:109433. 228
- 2. Korn, J., Schäckermann, D., Kirmann, T., et al. Baculovirus-free insect cell expression system for high 229 yield antibody and antigen production. Sci Rep 2020;10:1-10. 230
- Schmidt, F., Weisblum, Y., Muecksch, et al. Measuring SARS-CoV-2 neutralizing antibody activity using 231 3. 232 pseudotyped and chimeric viruses. J Exp Med 2020;217:e20201181.
- 233
- 234

Table S1. Demographic data of vaccinated individuals. 235

Groups	Number of	of Number of	Male/Female	Median age	Median
	individuals	samples		(IQR) ^a , years	sampling day
					after
					vaccination/infection (IQR)
vaccination					
(used for cutoff					
calculation)					
3 doses of	13	13	6/7	31 (27-56)	48 (12-92)
inactivated					
vaccine					
3 doses of	14	14	3/11	36 (30-53)	19 (15-29)
mRNA vaccine					
2 doses of	16	16	6/10	28 (26-29)	28 (19-39)
inactivated					
vaccine plus an					
mRNA vaccine					
booster					
3 doses of	5	8 (4 after the first	1/4	28 (27-32)	31 (19-82)
inactivated		dose of mRNA			
vaccine plus		vaccine and 4 after			
mRNA vaccine		the second dose of			
booster		mRNA vaccine)			
Infected plus	9	11 (7 after the first	5/4	37 (31-52)	31 (18-37)
mRNA vaccine		dose of mRNA			
		vaccine and 4 after			
		the second dose of			
		mRNA vaccine)			
Breakthrough	15	15	4/11	34 (27-53)	23 (17-34)
infection ^b					
Comparison of			Non-significant ^c	Non-significant ^d	Non-significant ^d
groups					

^a IQR: Interquartile range. 236

BA.1 wave. 238


^c Chi-square test for trend. 239

^d Kruskal-Wallis ANOVA. 240

^b After two or three doses of either inactivated or mRNA vaccine or a combination of both during the Omicron 237

Figure S1. Level of specific IgG antibodies against the receptor binding domain (RBD) of the G614 strain 241 and Omicron subvariants. 242

Level of specific IgG antibodies against the RBD of the G614 strain of severe acute respiratory syndrome 243 coronavirus 2 (SARS-CoV-2) (panel A) and the Omicron subvariants BA.1 (panel B), BA.2 (panel C), BA.4/5 244 (panel D), BO.1.1 (panel E), and XBB.1 (panel F) in participants who received three doses (3X) of inactivated 245 vaccine, three doses of mRNA vaccine, two doses (2X) of inactivated vaccine followed by an mRNA vaccine 246 247 booster, three doses of inactivated vaccine followed by one or two doses of mRNA vaccine booster, one or two doses of mRNA vaccine after infection (G614 wave) (Infected plus mRNA vaccine) or had experienced 248 breakthrough infection during the Omicron BA.1 wave (Breakthrough infection). The median antibody levels 249 250 and the ratio of the antibody levels of each group versus the group who received three doses of inactivated vaccine are shown on the top of each panel. Symbols represent individual samples and horizontal black lines 251 indicate the median. Whiskers indicate the interquartile range. A two-sided Mann-Whitney U test was used to 252 compare the antibody levels between three doses (3X) of inactivated vaccine group and other groups in each 253 254 panel. Antibody levels are presented as binding antibody units (BAU)/ml. The cutoff value (dashed line) is 255 calculated separately for each variant from samples of 12 pre-vaccinated, non-infected individuals.



perpetuity. All rights reserved. No reuse allowed without permission.

Figure S2. Level of receptor binding domain (RBD)-specific IgG antibodies (A) and neutralization activity (B) against G614 strain and Omicron subvariants.

Level of RBD-specific IgG antibodies and half-maximal neutralization titers (NT50) against the G614 strain of 260 SARS-CoV-2 and the Omicron subvariants BA.1, BA.2, BA.4/5, BQ.1.1, and XBB/XBB.1 in participants who 261 received three doses (3X) of inactivated vaccine, three doses of mRNA vaccine, two doses (2X) of inactivated 262 263 vaccine followed by an mRNA vaccine booster, three doses of inactivated vaccine followed by one or two doses of mRNA vaccine booster, one or two doses of mRNA vaccine after infection (G614 wave) (Infected plus 264 mRNA vaccine) or had experienced breakthrough infection during the Omicron BA.1 wave (Breakthrough 265 266 infection). The median antibody levels or neutralization titer and the ratio of the antibody levels or neutralization titer against G614 strain to that against each Omicron subvariant are shown on the top of each panel. Antibody 267 268 levels are presented as binding antibody units (BAU)/ml. Symbols represent individual samples and horizontal 269 black lines indicate the median. Whiskers indicate the interquartile range. The connecting lines between the 270 variants represent matched serum samples. A Wilcoxon matched-pairs signed rank test was used to compare the 271 antibody levels or neutralization titers against G614 strain to that against each Omicron subvariant in each panel. 272 The dashed line indicates the limit of detection.

